Contrasting of Momenta Pharmaceuticals Inc. (MNTA) and Flexion Therapeutics Inc. (NASDAQ:FLXN)

We are comparing Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) and Flexion Therapeutics Inc. (NASDAQ:FLXN) on their analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation. They both are Drugs – Generic companies, competing one another.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Momenta Pharmaceuticals Inc. 97.38M 12.31 154.06M -2.01 0.00
Flexion Therapeutics Inc. 13.34M 38.86 179.61M -4.80 0.00

We can see in table 1 the earnings per share (EPS), top-line revenue and valuation of Momenta Pharmaceuticals Inc. and Flexion Therapeutics Inc.


Table 2 represents Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) and Flexion Therapeutics Inc. (NASDAQ:FLXN)’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
Momenta Pharmaceuticals Inc. -158.20% -49.7% -37.9%
Flexion Therapeutics Inc. -1,346.40% -88.2% -46.9%

Volatility and Risk

Momenta Pharmaceuticals Inc.’s 2.28 beta indicates that its volatility is 128.00% more volatile than that of Standard and Poor’s 500. Flexion Therapeutics Inc.’s 16.00% more volatile than Standard and Poor’s 500 volatility due to the company’s 1.16 beta.


The current Quick Ratio of Momenta Pharmaceuticals Inc. is 5.4 while its Current Ratio is 5.4. Meanwhile, Flexion Therapeutics Inc. has a Current Ratio of 8.9 while its Quick Ratio is 8.7. Flexion Therapeutics Inc. is better positioned to pay off its short-term and long-term debts than Momenta Pharmaceuticals Inc.

Analyst Recommendations

Momenta Pharmaceuticals Inc. and Flexion Therapeutics Inc. Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Momenta Pharmaceuticals Inc. 0 0 1 3.00
Flexion Therapeutics Inc. 0 1 1 2.50

Momenta Pharmaceuticals Inc.’s upside potential currently stands at 186.89% and an $35 average target price. Flexion Therapeutics Inc. on the other hand boasts of a $34 average target price and a 148.36% potential upside. The data from earlier shows that analysts view suggest that Momenta Pharmaceuticals Inc. seems more appealing than Flexion Therapeutics Inc.

Insider & Institutional Ownership

1.8% are Momenta Pharmaceuticals Inc.’s share owned by insiders. Comparatively, Flexion Therapeutics Inc. has 0.6% of it’s share owned by insiders.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Momenta Pharmaceuticals Inc. 8.95% -10.91% -50.76% -46.36% 4.03% -7.53%
Flexion Therapeutics Inc. -12.08% 0.49% -33.95% -47.28% -43.05% -42.73%

For the past year Momenta Pharmaceuticals Inc. was less bearish than Flexion Therapeutics Inc.


On 10 of the 12 factors Momenta Pharmaceuticals Inc. beats Flexion Therapeutics Inc.

Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The companyÂ’s complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE. Its biosimilars programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M834, a biosimilar of ORENCIA for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis, as well as other biosimilar candidates. The companyÂ’s novel therapeutics programs include M254, a hyper-sialylated version of intravenous immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura, Kawasaki disease, and chronic inflammatory demyelinating polyneuropathy; M281, a fully-human monoclonal antibody that blocks the neonatal Fc receptor; and M230, a selective immunomodulator of Fc receptors candidate. It has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.

Flexion Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, a late-stage, intra-articular, extended-release investigational steroid treatment that has completed Phase 3 clinical trials for IA therapy for patients with moderate and severe osteoarthritis pain. The company was founded in 2007 and is headquartered in Burlington, Massachusetts.